Literature DB >> 2256719

DNA analysis, chemoresistance testing and hormone receptor levels as prognostic factors in advanced ovarian carcinoma.

J Schneider1, L Edler, W Kleine, M Volm.   

Abstract

Fifty patients with advanced (stage III or IV) ovarian carcinoma were followed-up until the date of their death or their fifth year of survival. Prognostic factors, including those currently in use, as well as ploidy and proliferation, chemoresistance testing and hormone receptor levels of the tumours were analysed for predictive value and independence from each other. In the univariate analysis, only stage, residual tumour, second-look status, chemoresistance, ploidy and proliferation were significantly correlated with survival. After being tested in a multivariate Cox regression model, however, only the results of chemoresistance testing at initiation of therapy, and second-look status at a later point, retained prognostic significance. Within the group of patients with a positive second-look, i.e., with the worst prognosis, the chemoresistance test was still able to discriminate between two subgroups with significantly different survival.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256719     DOI: 10.1007/bf02389589

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  19 in total

1.  The value of second-look operation in patients with advanced epithelial ovarian carcinoma.

Authors:  P Sevelda; C Dittrich; H Salzer
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

2.  Specific estrogen binding by the cytoplasm fof human breast carcinoma.

Authors:  S G Korenman; B A Dukes
Journal:  J Clin Endocrinol Metab       Date:  1970-05       Impact factor: 5.958

3.  The treatment of advanced ovarian carcinoma (II): interval reassessment operations during chemotherapy.

Authors:  A P Heintz; A T Van Oosterom; J B Trimbos; A Schaberg; E Van der Velde; M Nooy
Journal:  Gynecol Oncol       Date:  1988-07       Impact factor: 5.482

Review 4.  Clinical relevance of predictive tests for cancer chemotherapy.

Authors:  J Mattern; M Volm
Journal:  Cancer Treat Rev       Date:  1982-12       Impact factor: 12.111

5.  Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy.

Authors:  M Volm; K Wayss; M Kaufmann; J Mattern
Journal:  Eur J Cancer       Date:  1979-07       Impact factor: 9.162

6.  Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival. A five-year follow up study.

Authors:  M Volm; J Mattern; T Müller; P Drings
Journal:  Anticancer Res       Date:  1988 Jan-Feb       Impact factor: 2.480

7.  Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma.

Authors:  M Volm; P Drings; J Mattern; J Sonka; I Vogt-Moykopf; K Wayss
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

8.  Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer.

Authors:  O P Kallioniemi; T Hietanen; J Mattila; M Lehtinen; K Lauslahti; T Koivula
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

9.  DNA ploidy level and cell cycle distribution in ovarian cancer: relation to histopathological features of the tumor.

Authors:  O P Kallioniemi; J Mattila; R Punnonen; T Koivula
Journal:  Int J Gynecol Pathol       Date:  1988       Impact factor: 2.762

10.  Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.

Authors:  M Volm; P Drings; E W Hahn; J Mattern
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.